Brainstorm Cell Therapeutics hires leading scientist to advisory board
This article was originally published in Clinica
Brainstorm Cell Therapeutics, a firm focused on developing adult stem cell technologies and therapeutics for treatment of neurological conditions, has appointed Robert Brown to its scientific advisory board. Dr Brown, a professor of neurology at Harvard Medical School and Massachusetts General Hospital (MGH), is an expert in amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). He will help the New York, New York based company develop protocols for testing its lead products as ALS therapies. During his 30 years in the field, he has founded the Cecil Bay Laboratory for neuromuscular research at MGH and had his research published widely. In 2007 he won the Robert Wartenberg Lecture Award for excellence in clinically-relevant research, and will become chair of the medical school at the University of Massachusetts later this year.
You may also be interested in...
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.